Amgen autoimmune drug succeeds in late-stage trial

• Dazodalibep demonstrated clinically meaningful improvement in Sjogren's disease patients at week 48, with most adverse events being mild to moderate and few treatment discontinuations
• Sjogren's disease affects approximately 1% of the global population, causing extensive dryness of eyes and mouth, fatigue, and chronic pain, with no currently approved U.S. treatments
• Amgen faces competition from Novartis and Johnson & Johnson, which are also developing treatments for this condition; the trial is expected to complete in Q4 2026

Amgen Autoimmune Drug Succeeds in Late-Stage Trial

Amgen announced Tuesday that its experimental drug dazodalibep successfully met its primary endpoint in a Phase 3 trial for Sjogren's disease, demonstrating statistically significant and clinically meaningful reduction in disease activity at 48 weeks.

Key Trial Details:

Sjogren's disease is an autoimmune condition that attacks moisture-producing glands, causing severe dryness in eyes and mouth, along with fatigue and chronic pain. The disease affects approximately 1% of the global population, predominantly women. Most adverse events observed in the trial were mild to moderate, with few patient discontinuations reported.

Market Context:

Currently, no approved treatments exist in the United States for Sjogren's disease, representing a significant unmet medical need. Amgen faces competition from Novartis and Johnson & Johnson, both developing competing therapies for the same indication.

Timeline and Next Steps:

Amgen plans to present detailed trial data at an upcoming medical conference. The complete trial is expected to conclude in Q4 2026, which will likely precede regulatory submission for FDA approval.

Market Implications:

This positive trial result positions Amgen to potentially capture first-mover advantage in an untapped market affecting millions globally. Success in this indication could generate substantial revenue given the lack of approved alternatives and large patient population. The mild-to-moderate safety profile enhances commercial viability. Investors should monitor upcoming data presentations and competitive trial results from Novartis and J&J to assess Amgen's market positioning in this emerging therapeutic area.